Details for New Drug Application (NDA): 208653
✉ Email this page to a colleague
NDA 208653 describes APADAZ, which is a drug marketed by Zevra Therap and is included in one NDA. There are five patents protecting this drug. Additional details are available on the APADAZ profile page.
The generic ingredient in APADAZ is acetaminophen; benzhydrocodone hydrochloride. There are sixty-six drug master file entries for this compound. Additional details are available on the acetaminophen; benzhydrocodone hydrochloride profile page.
The generic ingredient in APADAZ is acetaminophen; benzhydrocodone hydrochloride. There are sixty-six drug master file entries for this compound. Additional details are available on the acetaminophen; benzhydrocodone hydrochloride profile page.
Summary for 208653
| Tradename: | APADAZ |
| Applicant: | Zevra Therap |
| Ingredient: | acetaminophen; benzhydrocodone hydrochloride |
| Patents: | 5 |
DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for 208653
Generic Entry Date for 208653*:
Constraining patent/regulatory exclusivity:
Dosage:
TABLET;ORAL |
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Profile for product number 001
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | TABLET;ORAL | Strength | 325MG;EQ 6.12MG BASE | ||||
| Approval Date: | Feb 23, 2018 | TE: | RLD: | Yes | |||||
| Patent: | 8,461,137 | Patent Expiration: | Feb 22, 2031 | Product Flag? | Y | Substance Flag? | Y | Delist Request? | |
| Patent: | 8,748,413 | Patent Expiration: | Jul 1, 2030 | Product Flag? | Y | Substance Flag? | Y | Delist Request? | |
| Patent: | 8,828,978 | Patent Expiration: | Jul 1, 2030 | Product Flag? | Y | Substance Flag? | Delist Request? | ||
Complete Access Available with Subscription
